Method for definition of CIS-TRANS status in double CEBPA mutations. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not include a full text component.

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over ...

Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...

ImmunityBio’s stock rose nearly 40% after it announced the Phase I data and Anktiva sales figures for 2025.

Optimally positioning CD19-directed therapies in the follicular lymphoma treatment sequence requires consideration of both efficacy and the risk of sacrificing future options. The introduction of CD19 ...

The patient with significant bone marrow involvement had complete bone morphological remission. In this patient in which 95% ...

Patients with Waldenström Non-Hodgkin lymphoma in the U.S. achieved durable complete responses of up to 15 months using a chemotherapy-free CD19 CAR-NK (chimeric antigen receptor natural killer) cell ...

SYDNEY & DUARTE, Calif.--(BUSINESS WIRE)--Imugene Ltd (ASX:IMU), an immuno-oncology company and City of Hope, a world-renowned independent cancer research and treatment center near Los Angeles, today ...

Credit: Getty Images. CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell therapy. The Food and Drug Administration (FDA) has granted Fast Track designation to CABA-201 for the treatment of ...

Early results from the ongoing QUILT-106 clinical trial (NCT06334991) show that the treatment combination of CD19 chimeric antigen receptor natural killer (CAR-NK) cells with rituximab (Rituxan) can ...